Swedish Cancer Institute

Swedish Edmonds Campus

Edmonds, WA

Sorting 5 by

Not yet accepting

DURGA-1

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Learn more
  • CAR T Cell
  • BCMA
  • CD19
  • Phase 1/2
  • Has results

Accepting patients

Iberdomide vs. Observation Post Ide-Cel CAR-T

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Learn more
  • CELMoD
  • Maintenance
  • Randomization
  • Phase 2

Accepting patients

Triplet Induction + 1 or 2-Drug Maintenance

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Learn more
  • Monoclonal Antibody
  • CD38
  • Randomization
  • Maintenance
  • Phase 3

Not currently accepting

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 3

Accepting patients

Early Detection Blood Tests

Blinded Reference Set for Multicancer Early Detection Blood Tests
Learn more
  • Observational Trial